GSK’s Strategic Approach to Deal-Making and Expansion Beyond Obesity with GLP-1s

GSK's CSO, Tony Wood, shared the company's science strategy behind deal-making and plans to leverage GLP-1s for indications beyond obesity3.
GSK aims to build on its existing portfolio by exploring new applications for GLP-1s, focusing on areas other than obesity3.
The company has shown interest in expanding its respiratory and immunology portfolio, as seen in its recent partnership with Flagship Pioneering1.
GSK's collaboration with Flagship Pioneering is designed to develop up to 10 new drugs and vaccines, starting with respiratory and immunology indications1.
The partnership leverages GSK's therapeutic area expertise and development capabilities with Flagship's ecosystem of bioplatform companies1.
GSK has previously demonstrated success with GLP-1s in diabetes management, as seen in the Harmony Outcomes study of albiglutide2.
The company's strategic approach to deal-making and R&D focuses on delivering best-in-class innovation and addressing unmet patient needs13.

Sources:

1. https://www.genengnews.com/topics/drug-discovery/gsk-flagship-launch-up-to-7b-development-partnership/

2. https://www.gsk.com/en-gb/media/press-releases/positive-results-from-harmony-outcomes-study-of-albiglutide-published-in-the-lancet/

3. https://www.newsnow.com/us/Business/Pharmaceuticals/GlaxoSmithKline